Fulvestrant (Faslodex AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects which works by down-regulating the estrogen receptor. It is administered as a once-monthly injection.
This page contains content from the copyrighted Wikipedia article "Fulvestrant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
